Dr. Head has been instrumental in the development of several of our new chemotherapy and immunotherapy programs. Dr. Head and Dr. Elliott are the co-developers and patent holders of one of the first patented autologous breast cancer vaccines in the United States.  His major goal is to implement translational research - the movement of laboratory-developed technologies into the clinical setting.  This is the taking of new therapies from cell culture to an accepted therapy for cancer patients.
 

As a tumor cell biologist, Dr. Head's specialties include:

• Cell culture research
• Animal research
• Human clinical research
• Innovative chemotherapies
• Immunotherapy/cancer vaccines
• Oncogene and antisense research
• Tumor markers

Dr. Head is an Adjunct Associate Professor of Biochemistry at Tulane University, an Adjunct Professor of Physical and Biological Sciences at Delta State University, and an active member of the American Association for Cancer Research and the American Society of Clinical Oncology. Although patients rarely meet Dr. Head, many of the new treatments we offer are the result of his work.